Menu
Search
|

Menu

Close
X

Ardelyx Inc ARDX.OQ (NASDAQ Stock Exchange Global Market)

4.68 USD
-0.36 (-7.14%)
As of Sep 17
Previous Close 5.04
Open 4.99
Volume 377,616
3m Avg Volume 159,398
Today’s High 5.04
Today’s Low 4.66
52 Week High 6.71
52 Week Low 1.62
Shares Outstanding (mil) 47.45
Market Capitalization (mil) 268.07
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.20 Mean rating from 5 analysts

KEY STATS

Revenue (mm, USD)
FY19
0
FY18
3
FY17
42
FY16
0
EPS (USD)
FY19
-0.824
FY18
-1.616
FY17
-1.358
FY16
-2.834
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.66
Price to Sales (TTM)
vs sector
--
7.91
Price to Book (MRQ)
vs sector
1.85
5.38
Price to Cash Flow (TTM)
vs sector
--
24.36
Total Debt to Equity (MRQ)
vs sector
0.00
14.55
LT Debt to Equity (MRQ)
vs sector
0.00
10.20
Return on Investment (TTM)
vs sector
-79.45
14.48
Return on Equity (TTM)
vs sector
-79.86
15.78

EXECUTIVE LEADERSHIP

David Mott
Independent Chairman of the Board, Since 2014
Salary: --
Bonus: --
Michael Raab
President, Chief Executive Officer, Director, Since 2009
Salary: $555,000.00
Bonus: --
Mark Kaufmann
Chief Financial Officer, Principal Accounting Officer, Since 2017
Salary: $281,875.00
Bonus: $37,068.00
Elizabeth Grammer
Senior Vice President, General Counsel, Since 2014
Salary: --
Bonus: --
Jeremy Caldwell
Chief Scientific Officer, Since 2017
Salary: $414,000.00
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

34175 Ardenwood Blvd
FREMONT   CA   94555-3653

Phone: +1510.7457047

Ardelyx, Inc. is a clinical-stage biopharmaceutical company. The Company's therapeutics focuses on addressing cardiorenal and gastrointestinal (GI) diseases. It operates through the research, development and commercialization of biopharmaceutical products segment. The Company's products line includes cardiorenal portfolio and gastrointestinal portfolio. The Company's cardiorenal portfolio includes two Phase III clinical product candidates, tenapanor in Phase III clinical development for treating hyperphosphatemia in end-stage renal disease (ESRD) patients on dialysis and RDX7675 in Phase III clinical development for treating hyperkalemia in chronic kidney disease (CKD) and heart failure patients. The cardiorenal portfolio includes tenapanor, RDX7675, RDX013 and RDX011. Its gastrointestinal portfolio is led by tenapanor for the treatment of irritable bowel syndrome with constipation (IBS-C). The gastrointestinal portfolio includes tenapanor, RDX8940, RDX011 and RDX023.

SPONSORED STORIES